MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results

LYON, France--(BUSINESS WIRE)---- $MAAT #Cancer--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today reported the 2024 full-year annual results and announces the completion of a private placement of €13 million at market price through the issuance of 2,131,148 new ordinary shares of the Company at a pri